Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2024-07-01
|
| Seri Bilgileri: | IJU Case Reports |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/iju5.12734 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|